SPIA
GRCE

Steward Partners Investment Advisory’s Grace Therapeutics GRCE Stock Holding History

Steward Partners Investment Advisory’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41
Closed -$190 – 4892
2026
Q1 		$190 Hold
41
– – ﹤0.01% 4317
2025
Q4 		$142 Hold
41
– – ﹤0.01% 4211
2025
Q3 		$122 Hold
41
– – ﹤0.01% 4183
2025
Q2 		$122 Buy
+41
New +$109 ﹤0.01% 4038

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.23B AUM 74.49% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Steward Partners Investment Advisory's GRCE Position: Q2 2026 in Review

Steward Partners Investment Advisory sold out of Grace Therapeutics (GRCE) in Q2 2026, closing a stake of 41 shares — an estimated $190 sold.

Steward Partners Investment Advisory first reported a position in GRCE in Q2 2025 and held it in 4 quarters. The position peaked at $190 in Q1 2026. 31 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Steward Partners Investment Advisory reported no remaining Grace Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 41 Grace Therapeutics shares in Q2 2026, an estimated $190.
  • Steward Partners Investment Advisory first reported a position in Grace Therapeutics in Q2 2025 and held it in 4 quarters.
  • Steward Partners Investment Advisory's Grace Therapeutics position peaked at $190 in Q1 2026.
  • 31 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.